BAFNAPH News Today

Bafna Pharmaceuticals Ltd Share Price

BAFNAPH

CMP as on 20-Feb-24 12:00
₹ 90

icon -1.30 | -1.42%

Open
₹ 94
Turnover(lac)
₹ 5
Prev. Close
₹ 91.30
Day's Vol (shares)
₹ 5,498
Day's Vol (shares)
₹ 90.00         ₹ 93.95

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
Image not found

Recommendation: Buy; Target price: ₹581

  • 16 February, 2024
  • 1:23 PM
  • less than a minute
Blog Image

As of the end of December, the promoters and group entities owned 63.71% of Vedanta Ltd.

  • 15 February, 2024
  • 10:37 AM
  • less than a minute
Image not found

Recommendation: Add; Target Price: ₹140

  • 14 February, 2024
  • 12:40 PM
  • less than a minute
Image not found

The proposed merger aims to establish a leading end-to-end CDMO and merchant API firm serving the pharmaceutical and specialty chemical markets

  • 08 February, 2024
  • 3:37 PM
  • less than a minute
Image not found

Recommendation: Buy; Target price: ₹2,840

  • 05 February, 2024
  • 2:28 PM
  • less than a minute
Image not found

Recommendation: Buy; Target price: ₹581

  • 02 February, 2024
  • 3:09 PM
  • less than a minute
Image not found

Bajaj Finserv Health Ltd. (BFS-Health), the wholly owned subsidiary of Bajaj Finserv (BJFIN), is acquiring 100% equity stake in Vidal Healthcare Services Private Ltd (VHC), for an enterprise value ₹3,250 Million.

  • 01 February, 2024
  • 10:53 AM
  • less than a minute
Image not found

Recommendation: Add; Target price: Rs 140

  • 29 January, 2024
  • 2:33 PM
  • less than a minute
Image not found

One area where we may expect some positive relief is on personal income tax. There may be some rationalisation of tax slabs and rates.

  • 26 January, 2024
  • 1:47 PM
  • less than a minute
Image not found

Currently, Envafolimab is being developed in the USA by Tracon Pharma in a pivotal trial for soft tissue sarcoma (STS) subtypes

  • 25 January, 2024
  • 3:25 PM
  • less than a minute